Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$152.51M$152.51M+16.5% vs Q1 2021 Net Income$25.62M$25.62M+349.9% vs Q1 2021 EPS Diluted$0.43$0.43+290.9% vs Q1 2021 Operating Income$1,967,000−85.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$3,451,000−90.1% Margins · derivedOperating margin1.3%−8.8 pt vs Q1 2021
Net margin16.8%+12.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end